Tariot PN, Lopera FS, Rios-Romenets S, Sink KM, et al. Safety and efficacy of crenezumab in cognitively unimpaired carriers of the PSEN1(Glu280Ala) mutation at risk for autosomal-dominant Alzheimer's disease in Colombia (API ADAD Colombia Trial): a phase 2, randomised, double-blind, placebo-controlled tri Lancet Neurol 2026;25:147-159.
PMID: 41579901